Boehringer Ingelheim ToMORROW® (cephapirin benzathine)

Boehringer Ingelheim

$5.49
Unit price per

ToMORROW gives dairy producers time-tested, broad-spectrum control against the harmful organisms that cause mastitis in dry cows.

ToMORROW has been an effective extended therapy treatment for more than 25 years, and studies have shown no change in the development of bacterial resistance.^1,2
ToMORROW has been shown by extensive clinical studies to be efficacious in the treatment of mastitis in dry cows, when caused by Streptococcus agalactiae and Staphylococcus aureus including penicillin-resistant strains.
ToMORROW is formulated with cephapirin benzathine to provide broad spectrum and long-acting therapy that dry cows need.

Presentations:

Pail containing 144 x 10 mL syringes and 144 convenient single use alcohol pads.
Cartons containing 12 x 10 mL syringes with 12 convenient single use alcohol pads.

Partial insertion reduces new infections.

With the Opti-Sert^® applicator tip, partial insertion reduces the incidence of new infections during the dry period.
Studies have shown that when infusing into the udder at a depth of 2 to 3 millimeters, as opposed to 5 or more millimeters, new intramammary infections can be reduced by as much as 50 percent.¹

Dosage Information

Infuse a 10 mL syringe (300 mg cephapirin activity per syringe) once each quarter has been completely milked out.

Safety Information:

TOMORROW should be administered with caution to subjects which have demonstrated some form of allergy, particularly to penicillin. Such reactions are rare; however, should they occur, consult your veterinarian.

Residue Warnings

For use in dry cows only.
Not to be used within 30 days of calving.
Milk from treated cows must not be used for food during the first 72 hours after calving.
Any animal infused with this product must not be slaughtered for food until 42 days after the latest infusion.

TOP REASONS TO USE
ToMORROW® (cephapirin benzathine)

1. A recent head-to-head study conducted on six dairy farms in four states shows less than 5 percent of all dry cow mastitis pathogens at dry-off were Gram-negative.¹

2. First-generation cephalosporins continue to maintain high effectiveness against Gram-positive organisms, and are more effective against those pathogens than third-generation cephalosporins.^2,3

3. Head-to-head study showed no difference in efficacy between the leading dry cow mastitis tubes.¹

4. Authors of the study concluded that "due to the lack of difference in efficacy, other factors should be used in the consideration of dry cow mastitis treatment, including prudent use of antibiotics, withhold times and value."¹

¹ Arruda AG, Godden S, Rapnicki P, et al. Randomized non-inferiority clinical trial evaluating three commercial dry cow mastitis preparations: I. Quarter-level outcomes. J Dairy Sci 2013;96(7):4419–4435.

² Prescott JF. Antimicrobial chemotherapy. In: Hirsh DC, Maclachlan NJ, Walker RL, eds. Veterinary microbiology. 2nd ed. Ames: Iowa State University Press, 2004;30.

³ Pol M, Ruegg PL. Relationship between antimicrobial drug usage and antimicrobial susceptibility of Gram-positive mastitis pathogens. J Dairy Sci 2007;90(1):262–273.

ToMORROW^® is a registered trademark of Boehringer Ingelheim Animal Health USA Inc. All other trademarks are property of their respective owners. ©2020 Boehringer Ingelheim Animal Health USA Inc. Duluth, GA. All Rights Reserved.
US-BOV-0383-2020